{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:33:16Z","timestamp":1790191996927,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"DOI":"10.7759\/cureus.43112","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T07:56:17Z","timestamp":1691481377000},"source":"Crossref","is-referenced-by-count":18,"title":["Lyme Disease and Post-treatment Lyme Disease Syndrome: Current and Developing Treatment Options"],"prefix":"10.7759","author":[{"given":"Norris C","family":"Talbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah J","family":"Spillers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Luther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsi","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenise G","family":"Soileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2022.03.004","article-title":"Epidemiology of Lyme disease","volume":"36","author":"Mead P","year":"2022","unstructured":"Mead P. Epidemiology of Lyme disease. Infect Dis Clin North Am. 2022, 36:495-521. 10.1016\/j.idc.2022.03.004","journal-title":"Infect Dis Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.20506\/rst.34.2.2380","article-title":"Lyme disease","volume":"34","author":"Chomel B","year":"2015","unstructured":"Chomel B. Lyme disease. Rev Sci Tech. 2015, 34:569-76. 10.20506\/rst.34.2.2380","journal-title":"Rev Sci Tech"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60103-7","article-title":"Lyme borreliosis","volume":"379","author":"Stanek G","year":"2012","unstructured":"Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet. 2012, 379:461-73. 10.1016\/S0140-6736(11)60103-7","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3201\/eid2708.204763","article-title":"Comparison of Lyme disease in the United States and Europe","volume":"27","author":"Marques AR","year":"2021","unstructured":"Marques AR, Strle F, Wormser GP. Comparison of Lyme disease in the United States and Europe. Emerg Infect Dis. 2021, 27:2017-24. 10.3201\/eid2708.204763","journal-title":"Emerg Infect Dis"},{"key":"ref5","unstructured":"CDC. Lyme disease. data and surveillance. (2022). Accessed: March 18, 2023: https:\/\/www.cdc.gov\/lyme\/datasurveillance\/index.html."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-018-3417-1","article-title":"Clinical spectrum of Lyme disease","volume":"38","author":"Cardenas-de la Garza JA","year":"2019","unstructured":"Cardenas-de la Garza JA, De la Cruz-Valadez E, Ocampo-Candiani J, Welsh O. Clinical spectrum of Lyme disease. Eur J Clin Microbiol Infect Dis. 2019, 38:201-8. 10.1007\/s10096-018-3417-1","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-6681-9","article-title":"Estimation of cumulative number of post-treatment Lyme disease cases in the US, 2016 and 2020","volume":"19","author":"DeLong A","year":"2019","unstructured":"DeLong A, Hsu M, Kotsoris H. Estimation of cumulative number of post-treatment Lyme disease cases in the US, 2016 and 2020. BMC Public Health. 2019, 19:352. 10.1186\/s12889-019-6681-9","journal-title":"BMC Public Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18648","article-title":"Lyme borreliosis as a trigger for autoimmune disease","volume":"13","author":"Yehudina Y","year":"2021","unstructured":"Yehudina Y, Trypilka S. Lyme borreliosis as a trigger for autoimmune disease. Cureus. 2021, 13:e18648. 10.7759\/cureus.18648","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100142","article-title":"Prevalence of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study","volume":"6","author":"Ursinus J","year":"2021","unstructured":"Ursinus J, Vrijmoeth HD, Harms MG, et al.. Prevalence of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study. Lancet Reg Health Eur. 2021, 6:100142. 10.1016\/j.lanepe.2021.100142","journal-title":"Lancet Reg Health Eur"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1024\/0040-5930\/a001386","article-title":"Lyme disease - epidemiology and pathophysiology. (Article in German)","volume":"79","author":"Martin Y","year":"2022","unstructured":"Martin Y, Zimmerli S. Lyme disease - epidemiology and pathophysiology. (Article in German). Ther Umsch. 2022, 79:441-7. 10.1024\/0040-5930\/a001386","journal-title":"Ther Umsch"},{"key":"ref11","unstructured":"CDC. Transmission of Lyme disease. (2023). Accessed. June 6, 2023: https:\/\/www.cdc.gov\/lyme\/transmission\/index.html."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050043","article-title":"Salivating for knowledge: potential pharmacological agents in tick saliva","volume":"5","author":"Hovius JW","year":"2008","unstructured":"Hovius JW, Levi M, Fikrig E. Salivating for knowledge: potential pharmacological agents in tick saliva. PLoS Med. 2008, 5:e43. 10.1371\/journal.pmed.0050043","journal-title":"PLoS Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.90","article-title":"Lyme borreliosis","volume":"2","author":"Steere AC","year":"2016","unstructured":"Steere AC, Strle F, Wormser GP, et al.. Lyme borreliosis. Nat Rev Dis Primers. 2016, 2:16090. 10.1038\/nrdp.2016.90","journal-title":"Nat Rev Dis Primers"},{"key":"ref14","unstructured":"Surveillance for Lyme disease--United States, 1992-2006. (2008). Accessed. June 3, 2023: https:\/\/stacks.cdc.gov\/view\/cdc\/7049."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3201\/eid2108.141878","article-title":"Geographic distribution and expansion of human Lyme disease, United States","volume":"21","author":"Kugeler KJ","year":"2015","unstructured":"Kugeler KJ, Farley GM, Forrester JD, Mead PS. Geographic distribution and expansion of human Lyme disease, United States. Emerg Infect Dis. 2015, 21:1455-7. 10.3201\/eid2108.141878","journal-title":"Emerg Infect Dis"},{"key":"ref16","unstructured":"CDC. Lyme disease map. (2022). Accessed. March 18, 2023: https:\/\/www.cdc.gov\/lyme\/datasurveillance\/lyme-disease-maps.html."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3201\/eid2710.210903","article-title":"Effects of COVID-19 pandemic on reported Lyme disease, United States, 2020","volume":"27","author":"McCormick DW","year":"2021","unstructured":"McCormick DW, Kugeler KJ, Marx GE, Jayanthi P, Dietz S, Mead P, Hinckley AF. Effects of COVID-19 pandemic on reported Lyme disease, United States, 2020. Emerg Infect Dis. 2021, 27:2715-7. 10.3201\/eid2710.210903","journal-title":"Emerg Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-019-0857-2","article-title":"Challenges in the diagnosis and treatment of Lyme disease","volume":"22","author":"Schoen RT","year":"2020","unstructured":"Schoen RT. Challenges in the diagnosis and treatment of Lyme disease. Curr Rheumatol Rep. 2020, 22:3. 10.1007\/s11926-019-0857-2","journal-title":"Curr Rheumatol Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2015.08.004","article-title":"Clinical manifestations and treatment of Lyme disease","volume":"35","author":"Sanchez JL","year":"2015","unstructured":"Sanchez JL. Clinical manifestations and treatment of Lyme disease. Clin Lab Med. 2015, 35:765-78. 10.1016\/j.cll.2015.08.004","journal-title":"Clin Lab Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08906-w","article-title":"A review of post-treatment Lyme disease syndrome and chronic Lyme disease for the practicing immunologist","volume":"62","author":"Wong KH","year":"2022","unstructured":"Wong KH, Shapiro ED, Soffer GK. A review of post-treatment Lyme disease syndrome and chronic Lyme disease for the practicing immunologist. Clin Rev Allergy Immunol. 2022, 62:264-71. 10.1007\/s12016-021-08906-w","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref21","unstructured":"Lyme disease diagnostics research. (2018). Accessed. March 18, 2023: https:\/\/www.niaid.nih.gov\/diseases-conditions\/lyme-disease-diagnostics-research."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1086\/654809","article-title":"Final report of the Lyme disease review panel of the Infectious Diseases Society of America","volume":"51","author":"Lantos PM","year":"2010","unstructured":"Lantos PM, Charini WA, Medoff G, et al.. Final report of the Lyme disease review panel of the Infectious Diseases Society of America. Clin Infect Dis. 2010, 51:1-5. 10.1086\/654809","journal-title":"Clin Infect Dis"},{"key":"ref23","unstructured":"Lyme disease. Erythema migrans rash. (2022). Accessed. March 18, 2023: https:\/\/www.cdc.gov\/lyme\/treatment\/erythema-migrans-rash.html."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1086\/649920","article-title":"Antibiotic treatment duration and long-term outcomes of patients with early Lyme disease from a Lyme disease-hyperendemic area","volume":"50","author":"Kowalski TJ","year":"2010","unstructured":"Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA. Antibiotic treatment duration and long-term outcomes of patients with early Lyme disease from a Lyme disease-hyperendemic area. Clin Infect Dis. 2010, 50:512-20. 10.1086\/649920","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02435-y","article-title":"Tetracycline-, doxycycline-, minocycline-induced pseudotumor cerebri and esophageal perforation","volume":"40","author":"Angelette AL","year":"2023","unstructured":"Angelette AL, Rando LL, Wadhwa RD, et al.. Tetracycline-, doxycycline-, minocycline-induced pseudotumor cerebri and esophageal perforation. Adv Ther. 2023, 40:1366-78. 10.1007\/s12325-023-02435-y","journal-title":"Adv Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-4-273","article-title":"Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease","volume":"117","author":"Nadelman RB","year":"1992","unstructured":"Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992, 117:273-80. 10.7326\/0003-4819-117-4-273","journal-title":"Ann Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.6.1173","article-title":"Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease","volume":"109","author":"Eppes SC","year":"2002","unstructured":"Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics. 2002, 109:1173-7. 10.1542\/peds.109.6.1173","journal-title":"Pediatrics"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1041","article-title":"Lyme borreliosis: diagnosis and management","volume":"369","author":"Kullberg BJ","year":"2020","unstructured":"Kullberg BJ, Vrijmoeth HD, van de Schoor F, Hovius JW. Lyme borreliosis: diagnosis and management. BMJ. 2020, 369:m1041. 10.1136\/bmj.m1041","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18703","article-title":"Post-treatment Lyme disease syndrome: need for diagnosis and treatment","volume":"13","author":"Maksimyan S","year":"2021","unstructured":"Maksimyan S, Syed MS, Soti V. Post-treatment Lyme disease syndrome: need for diagnosis and treatment. Cureus. 2021, 13:e18703. 10.7759\/cureus.18703","journal-title":"Cureus"},{"key":"ref30","unstructured":"Mayo Clinic. Mild cognitive impairment (MCI). (2023). Accessed. March 18, 2023: https:\/\/www.mayoclinic.org\/diseases-conditions\/mild-cognitive-impairment\/symptoms-causes\/syc-20354578."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00224","article-title":"The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome","volume":"4","author":"Rebman AW","year":"2017","unstructured":"Rebman AW, Bechtold KT, Yang T, Mihm EA, Soloski MJ, Novak CB, Aucott JN. The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome. Front Med (Lausanne). 2017, 4:224. 10.3389\/fmed.2017.00224","journal-title":"Front Med (Lausanne)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy329","article-title":"Adverse events associated with antibiotics and intravenous therapies for post-Lyme disease syndrome in a commercially insured sample","volume":"67","author":"Goodlet KJ","year":"2018","unstructured":"Goodlet KJ, Fairman KA. Adverse events associated with antibiotics and intravenous therapies for post-Lyme disease syndrome in a commercially insured sample. Clin Infect Dis. 2018, 67:1568-74. 10.1093\/cid\/ciy329","journal-title":"Clin Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6623a3","article-title":"Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic Lyme disease - United States","volume":"66","author":"Marzec NS","year":"2017","unstructured":"Marzec NS, Nelson C, Waldron PR, et al.. Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic Lyme disease - United States. MMWR Morb Mortal Wkly Rep. 2017, 66:607-9. 10.15585\/mmwr.mm6623a3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2016.1180829","article-title":"Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of 'chronic Lyme disease'","volume":"72","author":"De Wilde M","year":"2017","unstructured":"De Wilde M, Speeckaert M, Callens R, Van Biesen W. Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of 'chronic Lyme disease'. Acta Clin Belg. 2017, 72:133-7. 10.1080\/17843286.2016.1180829","journal-title":"Acta Clin Belg"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq116","article-title":"Vaccines against Lyme disease: what happened and what lessons can we learn?","volume":"52","author":"Poland GA","year":"2011","unstructured":"Poland GA. Vaccines against Lyme disease: what happened and what lessons can we learn?. Clin Infect Dis. 2011, 52:s253-8. 10.1093\/cid\/ciq116","journal-title":"Clin Infect Dis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.04.079","article-title":"Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: implications for vaccine development","volume":"35","author":"Izac JR","year":"2017","unstructured":"Izac JR, Oliver LD Jr, Earnhart CG, Marconi RT. Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: implications for vaccine development. Vaccine. 2017, 35:3178-85. 10.1016\/j.vaccine.2017.04.079","journal-title":"Vaccine"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz872","article-title":"Protective immunity and new vaccines for Lyme disease","volume":"70","author":"Gomes-Solecki M","year":"2020","unstructured":"Gomes-Solecki M, Arnaboldi PM, Backenson PB, et al.. Protective immunity and new vaccines for Lyme disease. Clin Infect Dis. 2020, 70:1768-73. 10.1093\/cid\/ciz872","journal-title":"Clin Infect Dis"},{"key":"ref38","unstructured":"CDC. Lyme disease vaccine. (2022). Accessed. February 10, 2023: https:\/\/www.cdc.gov\/lyme\/prev\/vaccine.html."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184357","article-title":"The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes","volume":"12","author":"Comstedt P","year":"2017","unstructured":"Comstedt P, Sch\u00fcler W, Meinke A, Lundberg U. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PLoS One. 2017, 12:e0184357. 10.1371\/journal.pone.0184357","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113294","article-title":"Design and development of a novel vaccine for protection against Lyme borreliosis","volume":"9","author":"Comstedt P","year":"2014","unstructured":"Comstedt P, Hanner M, Sch\u00fcler W, Meinke A, Lundberg U. Design and development of a novel vaccine for protection against Lyme borreliosis. PLoS One. 2014, 9:e113294. 10.1371\/journal.pone.0113294","journal-title":"PLoS One"},{"key":"ref41","unstructured":"An efficacy, safety, tolerability, immunogenicity, and lot-consistency clinical trial of a 6-valent OspA-based Lyme disease vaccine (VLA15) (Valor). (2022). Accessed. February 9, 2023: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05477524."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.11.065","article-title":"Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States","volume":"40","author":"Hook SA","year":"2022","unstructured":"Hook SA, Hansen AP, Niesobecki SA, et al.. Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States. Vaccine. 2022, 40:298-305. 10.1016\/j.vaccine.2021.11.065","journal-title":"Vaccine"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59600-4","article-title":"Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31","volume":"10","author":"Pothineni VR","year":"2020","unstructured":"Pothineni VR, Potula HS, Ambati A, et al.. Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31. Sci Rep. 2020, 10:3798. 10.1038\/s41598-020-59600-4","journal-title":"Sci Rep"},{"key":"ref44","unstructured":"PubChem. Azlocillin. (2023). Accessed. February 10, 2023: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6479523."},{"key":"ref45","unstructured":"CDC. Post-treatment Lyme disease syndrome. (2022). Accessed. February 10, 2023: https:\/\/www.cdc.gov\/lyme\/postlds\/index.html."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.011","article-title":"A selective antibiotic for Lyme disease","volume":"184","author":"Leimer N","year":"2021","unstructured":"Leimer N, Wu X, Imai Y, et al.. A selective antibiotic for Lyme disease. Cell. 2021, 184:5405-18.e16. 10.1016\/j.cell.2021.09.011","journal-title":"Cell"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02310-20","article-title":"A distinct microbiome signature in posttreatment Lyme disease patients","volume":"11","author":"Morrissette M","year":"2020","unstructured":"Morrissette M, Pitt N, Gonz\u00e1lez A, et al.. A distinct microbiome signature in posttreatment Lyme disease patients. mBio. 2020, 11:10.1128\/mBio.02310-20","journal-title":"mBio"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit942","article-title":"Xenodiagnosis for posttreatment Lyme disease syndrome: resolving the conundrum or adding to it?","volume":"58","author":"Bockenstedt LK","year":"2014","unstructured":"Bockenstedt LK, Radolf JD. Xenodiagnosis for posttreatment Lyme disease syndrome: resolving the conundrum or adding to it?. Clin Infect Dis. 2014, 58:946-8. 10.1093\/cid\/cit942","journal-title":"Clin Infect Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-07","article-title":"Persistence of Borrelia burgdorferi following antibiotic treatment in mice","volume":"52","author":"Hodzic E","year":"2008","unstructured":"Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother. 2008, 52:1728-36. 10.1128\/AAC.01050-07","journal-title":"Antimicrob Agents Chemother"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00864-15","article-title":"Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells","volume":"59","author":"Sharma B","year":"2015","unstructured":"Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells. Antimicrob Agents Chemother. 2015, 59:4616-24. 10.1128\/AAC.00864-15","journal-title":"Antimicrob Agents Chemother"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117207","article-title":"Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline","volume":"10","author":"Feng J","year":"2015","unstructured":"Feng J, Auwaerter PG, Zhang Y. Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline. PLoS One. 2015, 10:e0117207. 10.1371\/journal.pone.0117207","journal-title":"PLoS One"},{"key":"ref52","article-title":"Stationary phase persister\/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, post-treatment Lyme disease syndrome (PTLDS), and treatment failure","volume":"27","author":"Feng J","year":"2019","unstructured":"Feng J, Li T, Yee R, et al.. Stationary phase persister\/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, post-treatment Lyme disease syndrome (PTLDS), and treatment failure. Discov Med. 2019, 27:125-38.","journal-title":"Discov Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115293","article-title":"Aggregation of data from 4 clinical studies demonstrating efficacy of single-dose doxycycline postexposure for prevention of the spirochetal infections: Lyme disease, syphilis, and tick-borne relapsing fever","volume":"99","author":"Wormser GP","year":"2021","unstructured":"Wormser GP, Warshafsky S, Visintainer P. Aggregation of data from 4 clinical studies demonstrating efficacy of single-dose doxycycline postexposure for prevention of the spirochetal infections: Lyme disease, syphilis, and tick-borne relapsing fever. Diagn Microbiol Infect Dis. 2021, 99:115293. 10.1016\/j.diagmicrobio.2020.115293","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.06.032","article-title":"A single dose of doxycycline after an Ixodes ricinus tick bite to prevent Lyme borreliosis: an open-label randomized controlled trial","volume":"82","author":"Harms MG","year":"2021","unstructured":"Harms MG, Hofhuis A, Sprong H, et al.. A single dose of doxycycline after an Ixodes ricinus tick bite to prevent Lyme borreliosis: an open-label randomized controlled trial. J Infect. 2021, 82:98-104. 10.1016\/j.jinf.2020.06.032","journal-title":"J Infect"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.01.033","article-title":"Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: a prospective cohort study","volume":"116","author":"Aucott JN","year":"2022","unstructured":"Aucott JN, Yang T, Yoon I, Powell D, Geller SA, Rebman AW. Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: a prospective cohort study. Int J Infect Dis. 2022, 116:230-7. 10.1016\/j.ijid.2022.01.033","journal-title":"Int J Infect Dis"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10071314","article-title":"Kundalini yoga for post-treatment Lyme disease: a preliminary randomized study","volume":"10","author":"Murray L","year":"2022","unstructured":"Murray L, Alexander C, Bennett C, Kuvaldina M, Khalsa G, Fallon B. Kundalini yoga for post-treatment Lyme disease: a preliminary randomized study. Healthcare (Basel). 2022, 10:1314. 10.3390\/healthcare10071314","journal-title":"Healthcare (Basel)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2017.08.008","article-title":"Yoga, mindfulness-based stress reduction and stress-related physiological measures: a meta-analysis","volume":"86","author":"Pascoe MC","year":"2017","unstructured":"Pascoe MC, Thompson DR, Ski CF. Yoga, mindfulness-based stress reduction and stress-related physiological measures: a meta-analysis. Psychoneuroendocrinology. 2017, 86:152-68. 10.1016\/j.psyneuen.2017.08.008","journal-title":"Psychoneuroendocrinology"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268806007096","article-title":"The Lyme vaccine: a cautionary tale","volume":"135","author":"Nigrovic LE","year":"2007","unstructured":"Nigrovic LE, Thompson KM. The Lyme vaccine: a cautionary tale. Epidemiol Infect. 2007, 135:1-8. 10.1017\/S0950268806007096","journal-title":"Epidemiol Infect"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0183-8","article-title":"Design of a broadly reactive Lyme disease vaccine","volume":"5","author":"Kamp HD","year":"2020","unstructured":"Kamp HD, Swanson KA, Wei RR, et al.. Design of a broadly reactive Lyme disease vaccine. NPJ Vaccines. 2020, 5:33. 10.1038\/s41541-020-0183-8","journal-title":"NPJ Vaccines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/168604-lyme-disease-and-post-treatment-lyme-disease-syndrome-current-and-developing-treatment-options","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:30Z","timestamp":1707508890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/168604-lyme-disease-and-post-treatment-lyme-disease-syndrome-current-and-developing-treatment-options"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":59,"URL":"https:\/\/doi.org\/10.7759\/cureus.43112","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,8]]}}}